跳至主要内容
临床试验/CTRI/2023/01/049154
CTRI/2023/01/049154尚未招募未知

A comparative study to assess the effect of Empagliflozin versus Dapagliflozin on circulating markers of calcium-phosphate metabolism in uncontrolled Type2 diabetic patients on Metformin.

All India Institute Of Medical Sciences, Patna0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Previously diagnosed type 2 Diabetes Mellitus patient already on Metformin
  • (1000mg/day) >=3 month with FBS >=130 mg/dl or PPBS >=180mg/dl or HbA1C >=7%
  • 2. Age: >=18years and <=55 years
  • 3. Gender: Both

排除标准

  • 1.Patient already on diabetic treatment on drugs other than Metformin.
  • 2.Patient with Renal disease (S. Creatinine >=1.2mg/dl) Liver disease (ALT/AST >50IU)
  • 3.Pregnant and lactating women
  • 4.Patients unwilling/unable to give consent
  • 5.Patient on drugs which may cause hyperglycaemia like (Steroids, Beta2 agonist, Thiazides, Antipsychotics) .
  • 6.Patient on drugs causing hypoglycaemia (Beta blocker, Fluoroquinolones, Pentamidine).
  • 7. Patient on drugs causing derangement of vitamin D, PTH level (Phenytoin, phenobarbital, warfarin, Cyclophosphamide, Tamoxifen, Rifampicin, Antiviral drugs).
  • 8. Patient on vitamin D medication and calcium medication.
  • 9. Patient on drugs which derange calcium metabolism (Thiazides, Loop diuretics).
  • 10. Patient with vitamin D level less than 20 ng/ml.

研究者

发起方
All India Institute Of Medical Sciences, Patna

相似试验